Trial Profile
A Phase II Study Of SB939 In Patients With Translocation-Associated Recurrent/Metastatic Sarcomas.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Pracinostat (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- Acronyms IND200
- 30 Sep 2015 Status changed from completed to discontinued.
- 16 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 22 Jul 2013 Planned end date changed from 1 Nov 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.